GSK-Backed Sitryx Launches With Six Immunometabolism Eggs In Its Basket
GlaxoSmithKline, SV Health Investors and Sofinnova are among the backers of a new Oxford-based biotech which has raised $30m in series A financing and boasts a strong line-up of academic founders. CEO Neil Weir outlines Sitryx’s raison d’etre.
